Takeovers, restructurings and tougher regulation – lawyers working in the drugs industry are used to turbulent times. Alex Aldridge gets the perspective of the leading pharma clients facing up to major shifts within the industry
The pharmaceutical industry is going through a turbulent period. Patents protecting companies’ blockbuster drugs are expiring – according to consultancy firm Evaluate Pharma, around half of the $383bn (£255bn)-worth of patented drugs sold worldwide last year will lose patent protection in the next five years – while barriers preventing makers of generic drugs from selling their own versions of leading products continue to fall.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]